Search

Your search keyword '"Sottotetti, Elisa"' showing total 163 results
Start Over Author "Sottotetti, Elisa"
163 results on '"Sottotetti, Elisa"'

1. Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study

Author

Niger, Monica, Nichetti, Federico, Fornaro, Lorenzo, Pircher, Chiara, Morano, Federica, Palermo, Federica, Rimassa, Lorenza, Pressiani, Tiziana, Berardi, Rossana, Gardini, Andrea Casadei, Sperti, Elisa, Salvatore, Lisa, Melisi, Davide, Bergamo, Francesca, Siena, Salvatore, Mosconi, Stefania, Longarini, Rafaella, Arcangeli, Giuseppina, Corallo, Salvatore, Delliponti, Laura, Tamberi, Stefano, Fea, Elena, Brandi, Giovanni, Rapposelli, Ilario Giovanni, Salati, Massimiliano, Baili, Paolo, Miceli, Rosalba, Ljevar, Silva, Cavallo, Ilaria, Sottotetti, Elisa, Martinetti, Antonia, Busset, Michele Droz Dit, Sposito, Carlo, Di Bartolomeo, Maria, Pietrantonio, Filippo, de Braud, Filippo, and Mazzaferro, Vincenzo

Published
2024
Full Text
View/download PDF

2. A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study

Author

Niger, Monica, Nichetti, Federico, Fornaro, Lorenzo, Pircher, Chiara, Morano, Federica, Palermo, Federica, Rimassa, Lorenza, Pressiani, Tiziana, Berardi, Rossana, Gardini, Andrea Casadei, Sperti, Elisa, Salvatore, Lisa, Melisi, Davide, Bergamo, Francesca, Siena, Salvatore, Mosconi, Stefania, Longarini, Raffaella, Arcangeli, Giuseppina, Corallo, Salvatore, Delliponti, Laura, Tamberi, Stefano, Fea, Elena, Brandi, Giovanni, Rapposelli, Ilario Giovanni, Salati, Massimiliano, Baili, Paolo, Miceli, Rosalba, Ljevar, Silva, Cavallo, Ilaria, Sottotetti, Elisa, Martinetti, Antonia, Busset, Michele Droz Dit, Sposito, Carlo, Di Bartolomeo, Maria, Pietrantonio, Filippo, de Braud, Filippo, and Mazzaferro, Vincenzo

Published
2024
Full Text
View/download PDF

3. ALK Inhibitors in Patients With ALK Fusion–Positive GI Cancers: An International Data Set and a Molecular Case Series

Author

Ambrosini, Margherita, Del Re, Marzia, Manca, Paolo, Hendifar, Andrew, Drilon, Alexander, Harada, Guilherme, Ree, Anne Hansen, Klempner, Samuel, Mælandsmo, Gunhild Mari, Flatmark, Kjersti, Russnes, Hege G, Cleary, James M, Singh, Harshabad, Sottotetti, Elisa, Martinetti, Antonia, Randon, Giovanni, Sartore-Bianchi, Andrea, Capone, Iolanda, Milione, Massimo, Di Bartolomeo, Maria, and Pietrantonio, Filippo

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Digestive Diseases, Rare Diseases, Cancer, Aetiology, 2.1 Biological and endogenous factors, Carcinoma, Non-Small-Cell Lung, Crizotinib, Gastrointestinal Neoplasms, Humans, Lung Neoplasms, Prospective Studies, Protein Kinase Inhibitors, Oncology and carcinogenesis
Abstract

PurposeIn GI cancers, anaplastic lymphoma kinase (ALK) rearrangements are extremely less frequent than in non-small-cell lung cancer but may be important to offer personalized strategies of treatment in selected patients. Data about the activity and efficacy of ALK inhibitors (ALKi) in GI cancers are scarce.Materials and methodsWe assembled a clinical and molecular international data set of pretreated patients with metastatic or nonresectable cancers of GI primary tumor origin with documented ALK rearrangement treated with at least one line of ALKi. Measurable disease as per RECIST 1.1 was required for response analysis.ResultsPrimary tumor sites were distributed as follows: 5 (38%) pancreas, 3 (23%) right colon, and 1 (8%) for each one of gastric, duodenal, rectal, left colon, and biliary tract sites. Seven patients (54%) were treated with alectinib, 5 (38%) with crizotinib, and 1 (8%) with entrectinib. After disease progression, five patients (38%) received a subsequent ALKi treatment line, and at the time of data cutoff date, treatment was still ongoing in two patients. Five of 12 evaluable patients (41%) achieved a partial response to first-line ALKi, five patients (41%) had stable disease, and 2 (17%) had progressive disease. No complete responses were registered. At a median follow-up of 39.6 months (interquartile range: 19.8-59.5), the median progression-free survival was 5.0 months (95% CI, 3.68 to no response) and the median overall survival was 9.3 months (95% CI, 5.46 to no response).ConclusionTreatment with ALKi provides remarkable responses and clinical benefit in pretreated patients with ALK fusion-positive GI malignancies. Despite the rarity, ALK rearrangements represent an important therapeutic target in individual pretreated patients with GI solid tumors. Further work providing prospective clinical validation of this target is needed.

Published
2022

4. High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors

Author

Manglaviti, Sara, Bini, Marta, Apollonio, Giulia, Zecca, Ernesto, Galli, Giulia, Sangaletti, Sabina, Labianca, Alice, Sottotetti, Elisa, Brambilla, Marta, Occhipinti, Mario, Proto, Claudia, Prelaj, Arsela, Signorelli, Diego, De Toma, Alessandro, Viscardi, Giuseppe, Beninato, Teresa, Mazzeo, Laura, Bottiglieri, Achille, Leporati, Rita, Fotia, Giuseppe, Ganzinelli, Monica, Portararo, Paola, Garassino, Marina Chiara, de Braud, Filippo G.M., Lo Russo, Giuseppe, Torri, Valter, and Ferrara, Roberto

Published
2023
Full Text
View/download PDF

5. Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study

Author

Manca, Paolo, Corallo, Salvatore, Lonardi, Sara, Fucà, Giovanni, Busico, Adele, Leone, Alberto Giovanni, Corti, Francesca, Antoniotti, Carlotta, Procaccio, Letizia, Smiroldo, Valeria, Ratti, Margherita, Murialdo, Roberto, Racca, Patrizia, Pagani, Filippo, Randon, Giovanni, Martinetti, Antonia, Sottotetti, Elisa, Prisciandaro, Michele, Ambrosini, Margherita, Raimondi, Alessandra, Morano, Federica, and Pietrantonio, Filippo

Published
2022
Full Text
View/download PDF

6. Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology

Author

Manglaviti, Sara, Brambilla, Marta, Signorelli, Diego, Ferrara, Roberto, Lo Russo, Giuseppe, Proto, Claudia, Galli, Giulia, De Toma, Alessandro, Occhipinti, Mario, Viscardi, Giuseppe, Beninato, Teresa, Zattarin, Emma, Bini, Marta, Lobefaro, Riccardo, Massa, Giacomo, Bottiglieri, Achille, Apollonio, Giulia, Sottotetti, Elisa, Di Mauro, Rosa Maria, Trevisan, Benedetta, Ganzinelli, Monica, Fabbri, Alessandra, de Braud, Filippo G.M., Garassino, Marina Chiara, and Prelaj, Arsela

Published
2022
Full Text
View/download PDF

7. Supplementary Figure S5 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

Author

Hedayat, Somaieh, primary, Cascione, Luciano, primary, Cunningham, David, primary, Schirripa, Marta, primary, Lampis, Andrea, primary, Hahne, Jens C., primary, Tunariu, Nina, primary, Hong, Sung Pil, primary, Marchetti, Silvia, primary, Khan, Khurum, primary, Fontana, Elisa, primary, Angerilli, Valentina, primary, Delrieux, Mia, primary, Nava Rodrigues, Daniel, primary, Procaccio, Letizia, primary, Rao, Sheela, primary, Watkins, David, primary, Starling, Naureen, primary, Chau, Ian, primary, Braconi, Chiara, primary, Fotiadis, Nicos, primary, Begum, Ruwaida, primary, Guppy, Naomy, primary, Howell, Louise, primary, Valenti, Melanie, primary, Cribbes, Scott, primary, Kolozsvari, Bernadett, primary, Kirkin, Vladimir, primary, Lonardi, Sara, primary, Ghidini, Michele, primary, Passalacqua, Rodolfo, primary, Elghadi, Raghad, primary, Magnani, Luca, primary, Pinato, David J., primary, Di Maggio, Federica, primary, Ghelardi, Filippo, primary, Sottotetti, Elisa, primary, Vetere, Guglielmo, primary, Ciracì, Paolo, primary, Vlachogiannis, Georgios, primary, Pietrantonio, Filippo, primary, Cremolini, Chiara, primary, Cortellini, Alessio, primary, Loupakis, Fotios, primary, Fassan, Matteo, primary, and Valeri, Nicola, primary

Published
2024
Full Text
View/download PDF

8. Supplementary Video S1 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

Author

Hedayat, Somaieh, primary, Cascione, Luciano, primary, Cunningham, David, primary, Schirripa, Marta, primary, Lampis, Andrea, primary, Hahne, Jens C., primary, Tunariu, Nina, primary, Hong, Sung Pil, primary, Marchetti, Silvia, primary, Khan, Khurum, primary, Fontana, Elisa, primary, Angerilli, Valentina, primary, Delrieux, Mia, primary, Nava Rodrigues, Daniel, primary, Procaccio, Letizia, primary, Rao, Sheela, primary, Watkins, David, primary, Starling, Naureen, primary, Chau, Ian, primary, Braconi, Chiara, primary, Fotiadis, Nicos, primary, Begum, Ruwaida, primary, Guppy, Naomy, primary, Howell, Louise, primary, Valenti, Melanie, primary, Cribbes, Scott, primary, Kolozsvari, Bernadett, primary, Kirkin, Vladimir, primary, Lonardi, Sara, primary, Ghidini, Michele, primary, Passalacqua, Rodolfo, primary, Elghadi, Raghad, primary, Magnani, Luca, primary, Pinato, David J., primary, Di Maggio, Federica, primary, Ghelardi, Filippo, primary, Sottotetti, Elisa, primary, Vetere, Guglielmo, primary, Ciracì, Paolo, primary, Vlachogiannis, Georgios, primary, Pietrantonio, Filippo, primary, Cremolini, Chiara, primary, Cortellini, Alessio, primary, Loupakis, Fotios, primary, Fassan, Matteo, primary, and Valeri, Nicola, primary

Published
2024
Full Text
View/download PDF

9. Supplementary Tables S1-S19 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

Author

Hedayat, Somaieh, primary, Cascione, Luciano, primary, Cunningham, David, primary, Schirripa, Marta, primary, Lampis, Andrea, primary, Hahne, Jens C., primary, Tunariu, Nina, primary, Hong, Sung Pil, primary, Marchetti, Silvia, primary, Khan, Khurum, primary, Fontana, Elisa, primary, Angerilli, Valentina, primary, Delrieux, Mia, primary, Nava Rodrigues, Daniel, primary, Procaccio, Letizia, primary, Rao, Sheela, primary, Watkins, David, primary, Starling, Naureen, primary, Chau, Ian, primary, Braconi, Chiara, primary, Fotiadis, Nicos, primary, Begum, Ruwaida, primary, Guppy, Naomy, primary, Howell, Louise, primary, Valenti, Melanie, primary, Cribbes, Scott, primary, Kolozsvari, Bernadett, primary, Kirkin, Vladimir, primary, Lonardi, Sara, primary, Ghidini, Michele, primary, Passalacqua, Rodolfo, primary, Elghadi, Raghad, primary, Magnani, Luca, primary, Pinato, David J., primary, Di Maggio, Federica, primary, Ghelardi, Filippo, primary, Sottotetti, Elisa, primary, Vetere, Guglielmo, primary, Ciracì, Paolo, primary, Vlachogiannis, Georgios, primary, Pietrantonio, Filippo, primary, Cremolini, Chiara, primary, Cortellini, Alessio, primary, Loupakis, Fotios, primary, Fassan, Matteo, primary, and Valeri, Nicola, primary

Published
2024
Full Text
View/download PDF

10. Supplementary Methods S1 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

Author

Hedayat, Somaieh, primary, Cascione, Luciano, primary, Cunningham, David, primary, Schirripa, Marta, primary, Lampis, Andrea, primary, Hahne, Jens C., primary, Tunariu, Nina, primary, Hong, Sung Pil, primary, Marchetti, Silvia, primary, Khan, Khurum, primary, Fontana, Elisa, primary, Angerilli, Valentina, primary, Delrieux, Mia, primary, Nava Rodrigues, Daniel, primary, Procaccio, Letizia, primary, Rao, Sheela, primary, Watkins, David, primary, Starling, Naureen, primary, Chau, Ian, primary, Braconi, Chiara, primary, Fotiadis, Nicos, primary, Begum, Ruwaida, primary, Guppy, Naomy, primary, Howell, Louise, primary, Valenti, Melanie, primary, Cribbes, Scott, primary, Kolozsvari, Bernadett, primary, Kirkin, Vladimir, primary, Lonardi, Sara, primary, Ghidini, Michele, primary, Passalacqua, Rodolfo, primary, Elghadi, Raghad, primary, Magnani, Luca, primary, Pinato, David J., primary, Di Maggio, Federica, primary, Ghelardi, Filippo, primary, Sottotetti, Elisa, primary, Vetere, Guglielmo, primary, Ciracì, Paolo, primary, Vlachogiannis, Georgios, primary, Pietrantonio, Filippo, primary, Cremolini, Chiara, primary, Cortellini, Alessio, primary, Loupakis, Fotios, primary, Fassan, Matteo, primary, and Valeri, Nicola, primary

Published
2024
Full Text
View/download PDF

11. Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

Author

Hedayat, Somaieh, primary, Cascione, Luciano, additional, Cunningham, David, additional, Schirripa, Marta, additional, Lampis, Andrea, additional, Hahne, Jens C., additional, Tunariu, Nina, additional, Hong, Sung Pil, additional, Marchetti, Silvia, additional, Khan, Khurum, additional, Fontana, Elisa, additional, Angerilli, Valentina, additional, Delrieux, Mia, additional, Nava Rodrigues, Daniel, additional, Procaccio, Letizia, additional, Rao, Sheela, additional, Watkins, David, additional, Starling, Naureen, additional, Chau, Ian, additional, Braconi, Chiara, additional, Fotiadis, Nicos, additional, Begum, Ruwaida, additional, Guppy, Naomy, additional, Howell, Louise, additional, Valenti, Melanie, additional, Cribbes, Scott, additional, Kolozsvari, Bernadett, additional, Kirkin, Vladimir, additional, Lonardi, Sara, additional, Ghidini, Michele, additional, Passalacqua, Rodolfo, additional, Elghadi, Raghad, additional, Magnani, Luca, additional, Pinato, David J., additional, Di Maggio, Federica, additional, Ghelardi, Filippo, additional, Sottotetti, Elisa, additional, Vetere, Guglielmo, additional, Ciracì, Paolo, additional, Vlachogiannis, Georgios, additional, Pietrantonio, Filippo, additional, Cremolini, Chiara, additional, Cortellini, Alessio, additional, Loupakis, Fotios, additional, Fassan, Matteo, additional, and Valeri, Nicola, additional

Published
2024
Full Text
View/download PDF

12. Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial

Author

Platania, Marco, Pasini, Felice, Porcu, Luca, Boeri, Mattia, Verderame, Francesco, Modena, Yasmina, Del Conte, Alessandro, Nichetti, Federico, Garassino, Marina Chiara, Martinetti, Antonia, Sottotetti, Elisa, Cavanna, Luigi, Vattemi, Emanuela, Pozzessere, Daniele, Bertolini, Alessandro, Irtelli, Luciana, Verri, Carla, Sozzi, Gabriella, Proto, Claudia, Pastorino, Ugo, Torri, Valter, Fraccon, Anna Paola, Spinnato, Francesca, Signorelli, Diego, Lo Russo, Giuseppe, Tuzi, Alessandro, Gallucci, Rosaria, Cinieri, Saverio, Mencoboni, Manlio, Antonelli, Paola, Giacomelli, Luca, and de Braud, Filippo

Published
2019
Full Text
View/download PDF

13. Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases

Author

Marmorino, Federica, Prisciandaro, Michele, Giordano, Mirella, Ortolan, Elisa, Crucitta, Stefania, Manca, Paolo, Antoniotti, Carlotta, Valenti, Marta Maria, Danesi, Romano, Conca, Veronica, Mazzoli, Giacomo, Boccaccino, Alessandra, Carullo, Martina, Martinetti, Antonia, Sottotetti, Elisa, Masi, Gianluca, Sposito, Carlo, Zaffaroni, Nadia, Milione, Massimo, Fontanini, Gabriella, Del Re, Marzia, Pietrantonio, Filippo, and Cremolini, Chiara

Published
2022
Full Text
View/download PDF

14. Development of a Protocol for Single-Cell Analysis of Circulating Tumor Cells in Patients with Solid Tumors

Author

Reduzzi, Carolina, Motta, Rosita, Bertolini, Giulia, Miodini, Patrizia, Martinetti, Antonia, Sottotetti, Elisa, Daidone, Maria Grazia, Cappelletti, Vera, COHEN, IRUN R., Series editor, LAJTHA, ABEL, Series editor, LAMBRIS, JOHN D., Series editor, PAOLETTI, RODOLFO, Series editor, Magbanua, Mark Jesus M., editor, and Park, John W., editor

Published
2017
Full Text
View/download PDF

15. Adding fasting‐mimicking diet to first‐line carboplatin‐based chemotherapy is associated with better overall survival in advanced triple‐negative breast cancer patients: A subanalysis of the NCT03340935 trial

Author

Ligorio, Francesca, primary, Lobefaro, Riccardo, additional, Fucà, Giovanni, additional, Provenzano, Leonardo, additional, Zanenga, Lucrezia, additional, Nasca, Vincenzo, additional, Sposetti, Caterina, additional, Salvadori, Giulia, additional, Ficchì, Angela, additional, Franza, Andrea, additional, Martinetti, Antonia, additional, Sottotetti, Elisa, additional, Formisano, Barbara, additional, Depretto, Catherine, additional, Scaperrotta, Gianfranco, additional, Belfiore, Antonino, additional, Vingiani, Andrea, additional, Ferraris, Cristina, additional, Pruneri, Giancarlo, additional, de Braud, Filippo, additional, and Vernieri, Claudio, additional

Published
2023
Full Text
View/download PDF

17. Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients

Author

Ligorio, Francesca, Vingiani, Andrea, Torelli, Tommaso, Sposetti, Caterina, Drufuca, Lorenzo, Iannelli, Fabio, Zanenga, Lucrezia, Depretto, Catherine, Folli, Secondo, Scaperrotta, Gianfranco, Capri, Giuseppe, Bianchi, Giulia V., Ferraris, Cristina, Martelli, Gabriele, Maugeri, Ilaria, Provenzano, Leonardo, Nichetti, Federico, Agnelli, Luca, Lobefaro, Riccardo, Fucà, Giovanni, Fotia, Giuseppe, Mariani, Luigi, Morelli, Daniele, Ladisa, Vito, De Santis, Maria Carmen, Lozza, Laura, Trecate, Giovanna, Belfiore, Antonino, Brich, Silvia, Bertolotti, Alessia, Lorenzini, Daniele, Ficchì, Angela, Martinetti, Antonia, Sottotetti, Elisa, Arata, Alessio, Corsetto, Paola, Sorrentino, Luca, Rediti, Mattia, Salvadori, Giulia, Minucci, Saverio, Foiani, Marco, Apolone, Giovanni, Pagani, Massimiliano, Pruneri, Giancarlo, de Braud, Filippo, and Vernieri, Claudio

Published
2024
Full Text
View/download PDF

18. Adding fasting‐mimicking diet to first‐line carboplatin‐based chemotherapy is associated with better overall survival in advanced triple‐negative breast cancer patients: A subanalysis of the NCT03340935 trial.

Author

Ligorio, Francesca, Lobefaro, Riccardo, Fucà, Giovanni, Provenzano, Leonardo, Zanenga, Lucrezia, Nasca, Vincenzo, Sposetti, Caterina, Salvadori, Giulia, Ficchì, Angela, Franza, Andrea, Martinetti, Antonia, Sottotetti, Elisa, Formisano, Barbara, Depretto, Catherine, Scaperrotta, Gianfranco, Belfiore, Antonino, Vingiani, Andrea, Ferraris, Cristina, Pruneri, Giancarlo, and de Braud, Filippo

Subjects
TRIPLE-negative breast cancer, CANCER patients, OVERALL survival, LOW-calorie diet, CANCER chemotherapy
Abstract

Severe calorie restriction, in the form of cyclic fasting or fasting‐mimicking diets (FMDs), boosts the antitumor activity of cytotoxic chemotherapy in mouse models of triple‐negative breast cancer (TNBC). This effect is mostly mediated by fasting/FMD‐induced reduction of plasma glucose concentration and by a boost in antitumor immunity. However, clinical evidence that cyclic FMD may impact on the outcomes of advanced TNBC (aTNBC) patients is lacking. We compared the overall survival (OS) of 14 aTNBC patients receiving first‐line carboplatin‐gemcitabine plus cyclic FMD in the context of the NCT03340935 trial with the OS of 76 consecutive aTNBC patients treated with carboplatin‐based chemotherapy alone at Fondazione IRCCS Istituto Nazionale dei Tumori. Multivariable Cox regression models were used to adjust the prognostic impact of FMD for other prognostic variables. Patients undergoing cyclic FMD in combination with carboplatin‐gemcitabine had better OS when compared to patients receiving chemotherapy alone (median OS 30.3 months, 95% CI 18‐NR, vs 17.2 months, 95% CI 15.3‐25.1, log‐rank P value.041). Multivariable analysis confirmed an association between FMD use and better OS (HR: 0.40; 95% CI: 0.19‐0.86; P =.019) also after propensity score‐based matching according to patient ECOG PS and the presence of de novo metastatic disease (HR: 0.41; 95% CI: 0.21‐0.83; P =.013). Cyclic FMD in combination with first‐line chemotherapy may improve clinical outcomes in aTNBC patients. Our study paves the way for conducting phase II trials to investigate if cyclic FMD can increase the antitumor activity/efficacy of chemotherapy or chemoimmunotherapy in patients with early‐stage TNBC or aTNBC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Supplementary Tables from Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study

Author

Boeri, Mattia, primary, Milione, Massimo, primary, Proto, Claudia, primary, Signorelli, Diego, primary, Lo Russo, Giuseppe, primary, Galeone, Carlotta, primary, Verri, Carla, primary, Mensah, Mavis, primary, Centonze, Giovanni, primary, Martinetti, Antonia, primary, Sottotetti, Elisa, primary, Pastorino, Ugo, primary, Garassino, Marina Chiara, primary, and Sozzi, Gabriella, primary

Published
2023
Full Text
View/download PDF

20. Figure S1 from Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study

Author

Boeri, Mattia, primary, Milione, Massimo, primary, Proto, Claudia, primary, Signorelli, Diego, primary, Lo Russo, Giuseppe, primary, Galeone, Carlotta, primary, Verri, Carla, primary, Mensah, Mavis, primary, Centonze, Giovanni, primary, Martinetti, Antonia, primary, Sottotetti, Elisa, primary, Pastorino, Ugo, primary, Garassino, Marina Chiara, primary, and Sozzi, Gabriella, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Data from The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer

Author

Manca, Paolo, primary, Corallo, Salvatore, primary, Busico, Adele, primary, Lonardi, Sara, primary, Corti, Francesca, primary, Antoniotti, Carlotta, primary, Procaccio, Letizia, primary, Clavarezza, Matteo, primary, Smiroldo, Valeria, primary, Tomasello, Gianluca, primary, Murialdo, Roberto, primary, Sartore-Bianchi, Andrea, primary, Racca, Patrizia, primary, Pagani, Filippo, primary, Randon, Giovanni, primary, Martinetti, Antonia, primary, Sottotetti, Elisa, primary, Palermo, Federica, primary, Perrone, Federica, primary, Tamborini, Elena, primary, Prisciandaro, Michele, primary, Raimondi, Alessandra, primary, Di Bartolomeo, Maria, primary, Morano, Federica, primary, and Pietrantonio, Filippo, primary

Published
2023
Full Text
View/download PDF

22. Uterine tumor resembling sex-cord tumors of the ovary (UTROSCT): a case of long-term response to pazopanib

Author

Massa, Giacomo, primary, Tessari, Anna, additional, Damian, Silvia, additional, Duca, Matteo, additional, Tamborini, Elena, additional, Perrone, Federica, additional, Capone, Iolanda, additional, Paolini, Biagio, additional, Martinetti, Antonia, additional, Sottotetti, Elisa, additional, de Braud, Filippo, additional, Cresta, Sara, additional, and Pircher, Chiara, additional

Published
2022
Full Text
View/download PDF

25. PEOPLE (NTC03447678), a phase II trial of first-line, single-agent pembrolizumab in advanced NSCLC with low PD-L1: Clinical outcomes and association with circulating immune biomarkers.

Author

Lo Russo, Giuseppe, primary, Ganzinelli, Monica, additional, Sgambelluri, Francesco, additional, Galli, Francesca, additional, Prelaj, Arsela, additional, Manglaviti, Sara, additional, Bottiglieri, Achille, additional, Di Mauro, Rosa Maria, additional, Ferrara, Roberto, additional, Dumitrascu, Andra Diana, additional, Sottotetti, Elisa, additional, Martinetti, Antonia, additional, Fabbri, Alessandra, additional, Rulli, Eliana, additional, De Braud, Filippo G., additional, Torri, Valter, additional, Garassino, Marina Chiara, additional, Anichini, Andrea, additional, Proto, Claudia, additional, and Mortarini, Roberta, additional

Published
2022
Full Text
View/download PDF

26. sj-docx-3-tam-10.1177_17588359221108687 – Supplemental material for Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center

Author

Fucà, Giovanni, Lecchi, Mara, Ciniselli, Chiara Maura, Ottini, Arianna, Spagnoletti, Andrea, Mazzeo, Laura, Morelli, Daniele, Frati, Paola, Stroscia, Martina, Ebrahem, Elisabella, Sottotetti, Elisa, Galli, Giulia, D’Elia, Maria Grazia, Lobefaro, Riccardo, Ducceschi, Monika, Di Guardo, Lorenza, Bhoori, Sherrie, Provenzano, Salvatore, Platania, Marco, Niger, Monica, Colombo, Elena, Nichetti, Federico, Duca, Matteo, Rivoltini, Licia, Mortarini, Roberta, Baili, Paolo, Apolone, Giovanni, de Braud, Filippo, Verderio, Paolo, and Damian, Silvia

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-3-tam-10.1177_17588359221108687 for Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center by Giovanni Fuc’, Mara Lecchi, Chiara Maura Ciniselli, Arianna Ottini, Andrea Spagnoletti, Laura Mazzeo, Daniele Morelli, Paola Frati, Martina Stroscia, Elisabella Ebrahem, Elisa Sottotetti, Giulia Galli, Maria Grazia D’Elia, Riccardo Lobefaro, Monika Ducceschi, Lorenza Di Guardo, Sherrie Bhoori, Salvatore Provenzano, Marco Platania, Monica Niger, Elena Colombo, Federico Nichetti, Matteo Duca, Licia Rivoltini, Roberta Mortarini, Paolo Baili, Giovanni Apolone, Filippo de Braud, Paolo Verderio and Silvia Damian in Therapeutic Advances in Medical Oncology

Published
2022
Full Text
View/download PDF

27. sj-docx-4-tam-10.1177_17588359221108687 – Supplemental material for Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center

Author

Fucà, Giovanni, Lecchi, Mara, Ciniselli, Chiara Maura, Ottini, Arianna, Spagnoletti, Andrea, Mazzeo, Laura, Morelli, Daniele, Frati, Paola, Stroscia, Martina, Ebrahem, Elisabella, Sottotetti, Elisa, Galli, Giulia, D’Elia, Maria Grazia, Lobefaro, Riccardo, Ducceschi, Monika, Di Guardo, Lorenza, Bhoori, Sherrie, Provenzano, Salvatore, Platania, Marco, Niger, Monica, Colombo, Elena, Nichetti, Federico, Duca, Matteo, Rivoltini, Licia, Mortarini, Roberta, Baili, Paolo, Apolone, Giovanni, de Braud, Filippo, Verderio, Paolo, and Damian, Silvia

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-4-tam-10.1177_17588359221108687 for Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center by Giovanni Fuc’, Mara Lecchi, Chiara Maura Ciniselli, Arianna Ottini, Andrea Spagnoletti, Laura Mazzeo, Daniele Morelli, Paola Frati, Martina Stroscia, Elisabella Ebrahem, Elisa Sottotetti, Giulia Galli, Maria Grazia D’Elia, Riccardo Lobefaro, Monika Ducceschi, Lorenza Di Guardo, Sherrie Bhoori, Salvatore Provenzano, Marco Platania, Monica Niger, Elena Colombo, Federico Nichetti, Matteo Duca, Licia Rivoltini, Roberta Mortarini, Paolo Baili, Giovanni Apolone, Filippo de Braud, Paolo Verderio and Silvia Damian in Therapeutic Advances in Medical Oncology

Published
2022
Full Text
View/download PDF

28. sj-docx-6-tam-10.1177_17588359221108687 – Supplemental material for Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center

Author

Fucà, Giovanni, Lecchi, Mara, Ciniselli, Chiara Maura, Ottini, Arianna, Spagnoletti, Andrea, Mazzeo, Laura, Morelli, Daniele, Frati, Paola, Stroscia, Martina, Ebrahem, Elisabella, Sottotetti, Elisa, Galli, Giulia, D’Elia, Maria Grazia, Lobefaro, Riccardo, Ducceschi, Monika, Di Guardo, Lorenza, Bhoori, Sherrie, Provenzano, Salvatore, Platania, Marco, Niger, Monica, Colombo, Elena, Nichetti, Federico, Duca, Matteo, Rivoltini, Licia, Mortarini, Roberta, Baili, Paolo, Apolone, Giovanni, de Braud, Filippo, Verderio, Paolo, and Damian, Silvia

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-6-tam-10.1177_17588359221108687 for Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center by Giovanni Fuc’, Mara Lecchi, Chiara Maura Ciniselli, Arianna Ottini, Andrea Spagnoletti, Laura Mazzeo, Daniele Morelli, Paola Frati, Martina Stroscia, Elisabella Ebrahem, Elisa Sottotetti, Giulia Galli, Maria Grazia D’Elia, Riccardo Lobefaro, Monika Ducceschi, Lorenza Di Guardo, Sherrie Bhoori, Salvatore Provenzano, Marco Platania, Monica Niger, Elena Colombo, Federico Nichetti, Matteo Duca, Licia Rivoltini, Roberta Mortarini, Paolo Baili, Giovanni Apolone, Filippo de Braud, Paolo Verderio and Silvia Damian in Therapeutic Advances in Medical Oncology

Published
2022
Full Text
View/download PDF

29. sj-docx-7-tam-10.1177_17588359221108687 – Supplemental material for Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center

Author

Fucà, Giovanni, Lecchi, Mara, Ciniselli, Chiara Maura, Ottini, Arianna, Spagnoletti, Andrea, Mazzeo, Laura, Morelli, Daniele, Frati, Paola, Stroscia, Martina, Ebrahem, Elisabella, Sottotetti, Elisa, Galli, Giulia, D’Elia, Maria Grazia, Lobefaro, Riccardo, Ducceschi, Monika, Di Guardo, Lorenza, Bhoori, Sherrie, Provenzano, Salvatore, Platania, Marco, Niger, Monica, Colombo, Elena, Nichetti, Federico, Duca, Matteo, Rivoltini, Licia, Mortarini, Roberta, Baili, Paolo, Apolone, Giovanni, de Braud, Filippo, Verderio, Paolo, and Damian, Silvia

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-7-tam-10.1177_17588359221108687 for Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center by Giovanni Fuc’, Mara Lecchi, Chiara Maura Ciniselli, Arianna Ottini, Andrea Spagnoletti, Laura Mazzeo, Daniele Morelli, Paola Frati, Martina Stroscia, Elisabella Ebrahem, Elisa Sottotetti, Giulia Galli, Maria Grazia D’Elia, Riccardo Lobefaro, Monika Ducceschi, Lorenza Di Guardo, Sherrie Bhoori, Salvatore Provenzano, Marco Platania, Monica Niger, Elena Colombo, Federico Nichetti, Matteo Duca, Licia Rivoltini, Roberta Mortarini, Paolo Baili, Giovanni Apolone, Filippo de Braud, Paolo Verderio and Silvia Damian in Therapeutic Advances in Medical Oncology

Published
2022
Full Text
View/download PDF

30. sj-docx-2-tam-10.1177_17588359221108687 – Supplemental material for Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center

Author

Fucà, Giovanni, Lecchi, Mara, Ciniselli, Chiara Maura, Ottini, Arianna, Spagnoletti, Andrea, Mazzeo, Laura, Morelli, Daniele, Frati, Paola, Stroscia, Martina, Ebrahem, Elisabella, Sottotetti, Elisa, Galli, Giulia, D’Elia, Maria Grazia, Lobefaro, Riccardo, Ducceschi, Monika, Di Guardo, Lorenza, Bhoori, Sherrie, Provenzano, Salvatore, Platania, Marco, Niger, Monica, Colombo, Elena, Nichetti, Federico, Duca, Matteo, Rivoltini, Licia, Mortarini, Roberta, Baili, Paolo, Apolone, Giovanni, de Braud, Filippo, Verderio, Paolo, and Damian, Silvia

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-2-tam-10.1177_17588359221108687 for Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center by Giovanni Fuc’, Mara Lecchi, Chiara Maura Ciniselli, Arianna Ottini, Andrea Spagnoletti, Laura Mazzeo, Daniele Morelli, Paola Frati, Martina Stroscia, Elisabella Ebrahem, Elisa Sottotetti, Giulia Galli, Maria Grazia D’Elia, Riccardo Lobefaro, Monika Ducceschi, Lorenza Di Guardo, Sherrie Bhoori, Salvatore Provenzano, Marco Platania, Monica Niger, Elena Colombo, Federico Nichetti, Matteo Duca, Licia Rivoltini, Roberta Mortarini, Paolo Baili, Giovanni Apolone, Filippo de Braud, Paolo Verderio and Silvia Damian in Therapeutic Advances in Medical Oncology

Published
2022
Full Text
View/download PDF

31. sj-docx-1-tam-10.1177_17588359221108687 – Supplemental material for Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center

Author

Fucà, Giovanni, Lecchi, Mara, Ciniselli, Chiara Maura, Ottini, Arianna, Spagnoletti, Andrea, Mazzeo, Laura, Morelli, Daniele, Frati, Paola, Stroscia, Martina, Ebrahem, Elisabella, Sottotetti, Elisa, Galli, Giulia, D’Elia, Maria Grazia, Lobefaro, Riccardo, Ducceschi, Monika, Di Guardo, Lorenza, Bhoori, Sherrie, Provenzano, Salvatore, Platania, Marco, Niger, Monica, Colombo, Elena, Nichetti, Federico, Duca, Matteo, Rivoltini, Licia, Mortarini, Roberta, Baili, Paolo, Apolone, Giovanni, de Braud, Filippo, Verderio, Paolo, and Damian, Silvia

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tam-10.1177_17588359221108687 for Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center by Giovanni Fucà, Mara Lecchi, Chiara Maura Ciniselli, Arianna Ottini, Andrea Spagnoletti, Laura Mazzeo, Daniele Morelli, Paola Frati, Martina Stroscia, Elisabella Ebrahem, Elisa Sottotetti, Giulia Galli, Maria Grazia D’Elia, Riccardo Lobefaro, Monika Ducceschi, Lorenza Di Guardo, Sherrie Bhoori, Salvatore Provenzano, Marco Platania, Monica Niger, Elena Colombo, Federico Nichetti, Matteo Duca, Licia Rivoltini, Roberta Mortarini, Paolo Baili, Giovanni Apolone, Filippo de Braud, Paolo Verderio and Silvia Damian in Therapeutic Advances in Medical Oncology

Published
2022
Full Text
View/download PDF

32. sj-docx-5-tam-10.1177_17588359221108687 – Supplemental material for Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center

Author

Fucà, Giovanni, Lecchi, Mara, Ciniselli, Chiara Maura, Ottini, Arianna, Spagnoletti, Andrea, Mazzeo, Laura, Morelli, Daniele, Frati, Paola, Stroscia, Martina, Ebrahem, Elisabella, Sottotetti, Elisa, Galli, Giulia, D’Elia, Maria Grazia, Lobefaro, Riccardo, Ducceschi, Monika, Di Guardo, Lorenza, Bhoori, Sherrie, Provenzano, Salvatore, Platania, Marco, Niger, Monica, Colombo, Elena, Nichetti, Federico, Duca, Matteo, Rivoltini, Licia, Mortarini, Roberta, Baili, Paolo, Apolone, Giovanni, de Braud, Filippo, Verderio, Paolo, and Damian, Silvia

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-5-tam-10.1177_17588359221108687 for Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center by Giovanni Fuc’, Mara Lecchi, Chiara Maura Ciniselli, Arianna Ottini, Andrea Spagnoletti, Laura Mazzeo, Daniele Morelli, Paola Frati, Martina Stroscia, Elisabella Ebrahem, Elisa Sottotetti, Giulia Galli, Maria Grazia D’Elia, Riccardo Lobefaro, Monika Ducceschi, Lorenza Di Guardo, Sherrie Bhoori, Salvatore Provenzano, Marco Platania, Monica Niger, Elena Colombo, Federico Nichetti, Matteo Duca, Licia Rivoltini, Roberta Mortarini, Paolo Baili, Giovanni Apolone, Filippo de Braud, Paolo Verderio and Silvia Damian in Therapeutic Advances in Medical Oncology

Published
2022
Full Text
View/download PDF

33. Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center

Author

Fucà, Giovanni, primary, Lecchi, Mara, additional, Ciniselli, Chiara Maura, additional, Ottini, Arianna, additional, Spagnoletti, Andrea, additional, Mazzeo, Laura, additional, Morelli, Daniele, additional, Frati, Paola, additional, Stroscia, Martina, additional, Ebrahem, Elisabella, additional, Sottotetti, Elisa, additional, Galli, Giulia, additional, D’Elia, Maria Grazia, additional, Lobefaro, Riccardo, additional, Ducceschi, Monika, additional, Di Guardo, Lorenza, additional, Bhoori, Sherrie, additional, Provenzano, Salvatore, additional, Platania, Marco, additional, Niger, Monica, additional, Colombo, Elena, additional, Nichetti, Federico, additional, Duca, Matteo, additional, Rivoltini, Licia, additional, Mortarini, Roberta, additional, Baili, Paolo, additional, Apolone, Giovanni, additional, de Braud, Filippo, additional, Verderio, Paolo, additional, and Damian, Silvia, additional

Published
2022
Full Text
View/download PDF

34. Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study

Author

Manca, Paolo, primary, Corallo, Salvatore, additional, Lonardi, Sara, additional, Fucà, Giovanni, additional, Busico, Adele, additional, Leone, Alberto Giovanni, additional, Corti, Francesca, additional, Antoniotti, Carlotta, additional, Procaccio, Letizia, additional, Smiroldo, Valeria, additional, Ratti, Margherita, additional, Murialdo, Roberto, additional, Racca, Patrizia, additional, Pagani, Filippo, additional, Randon, Giovanni, additional, Martinetti, Antonia, additional, Sottotetti, Elisa, additional, Prisciandaro, Michele, additional, Ambrosini, Margherita, additional, Raimondi, Alessandra, additional, Morano, Federica, additional, and Pietrantonio, Filippo, additional

Published
2021
Full Text
View/download PDF

37. Angiopoietin-2 early increase to predict benefit from regorafenib in metastatic colorectal cancer (mCRC) patients: The prospective REGOLAND study.

Author

Marmorino, Federica, primary, Antoniotti, Carlotta, additional, Boccaccino, Alessandra, additional, Antista, Maria, additional, Zaffaroni, Nadia, additional, Zucchelli, Gemma, additional, Martinetti, Antonia, additional, Campi, Elisa, additional, Rossini, Daniele, additional, Sottotetti, Elisa, additional, Borelli, Beatrice, additional, Corti, Francesca, additional, Conca, Veronica, additional, Moretto, Roberto, additional, Germani, Marco Maria, additional, Falcone, Alfredo, additional, Giordano, Mirella, additional, Masi, Gianluca, additional, Pietrantonio, Filippo, additional, and Cremolini, Chiara, additional

Published
2021
Full Text
View/download PDF

38. The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer

Author

Manca, Paolo, primary, Corallo, Salvatore, additional, Busico, Adele, additional, Lonardi, Sara, additional, Corti, Francesca, additional, Antoniotti, Carlotta, additional, Procaccio, Letizia, additional, Clavarezza, Matteo, additional, Smiroldo, Valeria, additional, Tomasello, Gianluca, additional, Murialdo, Roberto, additional, Sartore-Bianchi, Andrea, additional, Racca, Patrizia, additional, Pagani, Filippo, additional, Randon, Giovanni, additional, Martinetti, Antonia, additional, Sottotetti, Elisa, additional, Palermo, Federica, additional, Perrone, Federica, additional, Tamborini, Elena, additional, Prisciandaro, Michele, additional, Raimondi, Alessandra, additional, Di Bartolomeo, Maria, additional, Morano, Federica, additional, and Pietrantonio, Filippo, additional

Published
2021
Full Text
View/download PDF

39. Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma

Author

Ratta, Raffaele, primary, Verzoni, Elena, additional, Mennitto, Alessia, additional, Pantano, Francesco, additional, Martinetti, Antonia, additional, Raimondi, Alessandra, additional, Sepe, Pierangela, additional, Sottotetti, Elisa, additional, Mennitto, Roberta, additional, Morelli, Daniele, additional, Santini, Daniele, additional, de Braud, Filippo G., additional, and Procopio, Giuseppe, additional

Published
2020
Full Text
View/download PDF

40. Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience

Author

Sepe, Pierangela, primary, Verzoni, Elena, additional, Miodini, Patrizia, additional, Claps, Melanie, additional, Ratta, Raffaele, additional, Martinetti, Antonia, additional, Mennitto, Roberta, additional, Sottotetti, Elisa, additional, Procopio, Giuseppe, additional, Cappelletti, Vera, additional, and Daidone, Maria Grazia, additional

Published
2019
Full Text
View/download PDF

41. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study

Author

Boeri, Mattia, primary, Milione, Massimo, additional, Proto, Claudia, additional, Signorelli, Diego, additional, Lo Russo, Giuseppe, additional, Galeone, Carlotta, additional, Verri, Carla, additional, Mensah, Mavis, additional, Centonze, Giovanni, additional, Martinetti, Antonia, additional, Sottotetti, Elisa, additional, Pastorino, Ugo, additional, Garassino, Marina Chiara, additional, and Sozzi, Gabriella, additional

Published
2019
Full Text
View/download PDF

42. Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma

Author

Ratta, Raffaele, Verzoni, Elena, Mennitto, Alessia, Pantano, Francesco, Martinetti, Antonia, Raimondi, Alessandra, Sepe, Pierangela, Sottotetti, Elisa, Mennitto, Roberta, Morelli, Daniele, Santini, Daniele, de Braud, Filippo G., and Procopio, Giuseppe

Abstract

Background: Cabozantinib strongly inhibits osteoclast differentiation and bone resorption in vitro. We aimed to evaluate its effect on bone turnover markers (BTMs) in metastatic renal cell carcinoma.Methods: This is a monocentric prospective study on patients with mRCC treated with cabozantinib between October 2016 and July 2018. We collected blood samples at baseline and after 3 and 6 months of treatment. We compared sets of data obtained from plasma samples in the whole population with unpaired 2-tailed Student ttests and data for a subset of patients for which all timepoints were available with paired 2-tailed Student ttests. We used the Kaplan-Meier method for survival analyses and the log-rank test to compare the curves.Results: Our analysis included 39 patients. At month 3, the mean C-terminal cross-linked telopeptides of type I collagen (CTx) and the mean N-terminal propeptide of type 1 collagen (PINP) levels were significantly decreased in the whole population (p= 0.013 and p< 0.0001, respectively), as well as at paired analysis (p= 0.015 and p= 0.045, respectively). No differences were observed between baseline and 6 months (p= 0.053 and p= 0.087, respectively). After 3 months, the mean parathyroid hormone (PTH) levels significantly increased in the whole population (p= 0.004), as well as at paired analysis; the mean PTH levels increased significantly at 3 and 6 months, respectively (p= 0.019 and p= 0.041, respectively). Changes in BTM levels were not associated with outcome.Conclusions: Cabozantinib significantly reduced bone resorption as demonstrated by the decrease of CTx and showed a transient secondary increase of PTH.

Published
2021
Full Text
View/download PDF

45. A randomized phase II trial of maintenance oral metronomic vinorelbine versus close observation in advanced non-small cell lung cancer (NSCLC) following platinum-based chemotherapy: MA.NI.LA. trial.

Author

Platania, Marco, primary, Nichetti, Federico, additional, Porcu, Luca, additional, Pasini, Felice, additional, Boeri, Mattia, additional, Modena, Yasmina, additional, Del Conte, Alessandro, additional, Martinetti, Antonia, additional, Sottotetti, Elisa, additional, Pozzessere, Daniele, additional, Vattemi, Emanuela, additional, Verderame, Francesco, additional, Cavanna, Luigi, additional, Fraccon, Anna Paola, additional, Formisano, Barbara, additional, Gallucci, Rosaria, additional, Lo Russo, Giuseppe, additional, Torri, Valter, additional, and De Braud, Filippo G., additional

Published
2018
Full Text
View/download PDF

48. Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase

Author

Falvella, Felicia, primary, Caporale, Marta, additional, Cheli, Stefania, additional, Martinetti, Antonia, additional, Berenato, Rosa, additional, Maggi, Claudia, additional, Niger, Monica, additional, Ricchini, Francesca, additional, Bossi, Ilaria, additional, Bartolomeo, Maria, additional, Sottotetti, Elisa, additional, Bernardi, Francesca, additional, de Braud, Filippo, additional, Clementi, Emilio, additional, and Pietrantonio, Filippo, additional

Published
2015
Full Text
View/download PDF

49. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory,RAS-BRAFwild-type colorectal cancer receiving cetuximab or panitumumab

Author

Musella, Valeria, primary, Pietrantonio, Filippo, additional, Di Buduo, Eleonora, additional, Iacovelli, Roberto, additional, Martinetti, Antonia, additional, Sottotetti, Elisa, additional, Bossi, Ilaria, additional, Maggi, Claudia, additional, Di Bartolomeo, Maria, additional, de Braud, Filippo, additional, Daidone, Maria Grazia, additional, and Cappelletti, Vera, additional

Published
2015
Full Text
View/download PDF

50. Effect of SNPs in TMPRSS2 to severe COVID-19 in patients with prostate cancer.

Author

Claps, Melanie, Jachetti, Elena, Badenchini, Fabio, Taglialatela, Ida, Tripodi, Irene, Ferri, Renata, Minnai, Francesca, Colombo, Francesca, Valenti, Luca, Malvestiti, Francesco, Sottotetti, Elisa, Zanichelli, Anna, Vela, Chiara, Rollo, Luisa, Bottiglieri, Achille, Sepe, Pierangela, Stellato, Marco, Guadalupi, Valentina, Procopio, Giuseppe, and Verzoni, Elena

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results